PDCD1 and neoplasm: The interaction of PD-1+ NK with PD-L1 on tumor cells leading to a decrease in NK cell response and a more aggressive tumor in vivo, has also been confirmed in many other types of cancers, including digestive cancer, melanomas, multiple myelomas, and lymphomas17,44–46.